Monotherapy or combination therapy of isavuconazole and micafungin for treating murine mucormycosis | Zendy

Teclegiorgis Gebremariam | Zendy; Nathan P. Wiederhold | Zendy; Abdullah Alqarihi | Zendy; Priya Uppuluri | Zendy; Nkechi Azie | Zendy; John E. Edwards | Zendy; Ashraf S. Ibrahim | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Monotherapy or combination therapy of isavuconazole and micafungin for treating murine mucormycosis

Author(s) -

Teclegiorgis Gebremariam,

Nathan P. Wiederhold,

Abdullah Alqarihi,

Priya Uppuluri,

Nkechi Azie,

John E. Edwards,

Ashraf S. Ibrahim

Publication year - 2016

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkw433

Subject(s) - mucormycosis , mucor circinelloides , micafungin , rhizopus , combination therapy , amphotericin b , mucor , mucorales , pharmacology , medicine , mycosis , microbiology and biotechnology , biology , immunology , surgery , aspergillus , antifungal , food science , fermentation

Previously we demonstrated the benefit of isavuconazole in treating murine mucormycosis due to Rhizopus. We wanted to determine the efficacy of isavuconazole in treating murine mucormycosis caused by Mucor, the second most common cause of the disease. Furthermore, because we previously determined that Rhizopus possesses the target enzyme for echinocandins and micafungin has activity against murine mucormycosis, we compared the activity of combination therapy (isavuconazole + micafungin) with placebo, either drug alone or standard therapy of liposomal amphotericin B (LAmB) in treating pulmonary murine mucormycosis caused by Rhizopus delemar.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research